



TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call

July 16, 2026 8:05 PM EDT

WESTMINSTER, Colo.--(BUSINESS WIRE)--Jul. 16, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call.

Parties interested in participating by phone should register using this [online form](#). After registering for the call, dial-in details will be provided in an auto-generated email containing a link to the conference phone number along with a PIN. The event will also be webcast live on the [investor relations section](#) of TriSalus' website. A replay will also be available on the website following the event.

About TriSalus Life Sciences

TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolid, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's three FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNa® Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolid, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolid delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolid, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260716428515/en/>

For Media Inquiries:

Andrea Marasso
Vice President, Marketing
andrea.marasso@trisaluslifesci.com

For Investor Inquiries:

David Patience
Chief Financial Officer
investor.relations@trisaluslifesci.com

Source: TriSalus Life Sciences